Mankind Pharma Q1 Results Preview: Revenue Likely To Rise, Net Profit May Decline

Mankind Pharma Ltd. is set to announce its financial results for the April-June quarter on Thursday. Brokerages expect domestic business and exports business growth post Bharat Serum Vaccine acquisition in earnings.

As per Bloomberg estimates, Mankind Pharma's consolidated revenue for the first quarter is expected to rise year-on-year to Rs 3,605.53 crore, compared to Rs 2,893.42 crore a year ago. The company's net profit is expected to fall to Rs 446.71 crore for the quarter.

• Revenue seen higher at Rs 3,605.53 crore versus Rs 2,893.42 crore.

• Ebitda seen higher at Rs 900.11 crore versus Rs 681.76 crore.

• Margin seen at 25% versus 23.6%.

• Net profit seen at Rs 446.71 crore versus Rs 536.49 crore.

• Sustained outperformance vs IPM to support organic growth of 10% for ex-BSV acquisition in Q1.

• Expect BSV revenue of Rs 4.7 billion in Q1.

• Assumed organic Rx growth of 10% year-on-year and 13% growth in CHL business + BSV's domestic revenue will contribute 6.6% to India revenue in Q1.

• BSV acquisition driven strong growth in exports business.

• BSV's export revenue will contribute approximately 7% to overall revenue in Q1.

• We are projecting 5% year-on-year growth in organic exports in Q1.

• Margins to improve 175bps quarter-on-quarter on account of higher India business sales mix.

• The brokerage expects overall top line growth of 8%, on ex-BSV.

• India business expected to deliver 8% growth on ex-BSV basis as the benefits from corrective measures implemented in acute division will play out gradually over FY26E.

• Consumer segment expected to deliver low-teen growth and exports ex-BSV to grow at mid-single-digits.

• Consolidated sales growth built at 24% year-on-year and Ebitda margins at 24.5% as we expect cost benefits of recent restructuring, BSV integration to come in a staggered manner.